PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.

Evidence

The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis

Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Title: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis Background: The BluePrint (BP), 80-gene signature, provides insight into the intrinsic subtype of early-stage breast cancer (EBC). This study evaluates Read More

Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting

Publication: ASBRS 2025 Authors: Thompson et al. Title: Real World Evidence of MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting Introduction: Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and Read More

Successful Unconventional Precision Treatment of Inflammatory Hormone Receptor-Positive Breast Cancer Guided by Molecular Profiling

Publication: npj Precision Oncology | (2025) 9:63 Authors: Jailan Elayoubi , Yu Zong & Erich J. Schwartz Title: Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling Abstract: We present a unique case of locally advanced, inflammatory hormone receptor (HR) positive, human epidermal growth Read More

Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX

Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce Oโ€™Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrintยฎ Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: โ€ข Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More

Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers โ€“ A FLEX sub study

Publication: ESMO Breast 2024 Authors:ย Virginia F. Borges1, Elena Shagisultanova1, Joyce O'Shaughnessy2, Adam Brufsky3, Reshma L. Mahtani4, Kent Hoskins5, Hannah Linden6, Nina D'Abreo7, Sahra Uygun8, Lavanya Samraj8, William Audeh8 University of Colorado Anschutz Medical Campus, Aurora CO 2. Baylor University Medical Center, Dallas, TX 3. University of Pittsburgh Medical Center Read More